Real-World Observational Review of Andexanet Alfa Prescribing and Utilization Outcomes at a Community Teaching Hospital

OBJECTIVES: Andexanet alfa is the first approved antidote in the management of life-threatening bleeds in patients treated with Xa inhibitors. The ANNEXA-4 study was successful in reducing factor Xa levels during time of administration but lacked correlation to improved patient outcomes. Given its n...

Descripción completa

Detalles Bibliográficos
Autores principales: Sobolewski, Kristine A., Brophy, Alison, Choi, Seohyun (Claudia), Opsha, Yekaterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Basic Science Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021330/
https://www.ncbi.nlm.nih.gov/pubmed/33834167
http://dx.doi.org/10.1097/CCE.0000000000000356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021330/
https://www.ncbi.nlm.nih.gov/pubmed/33834167
http://dx.doi.org/10.1097/CCE.0000000000000356

Ejemplares similares